ArticleFrontiers in immunology2025
Integrated multi-omics reveals GABARAP-mediated mitophagy and pyruvate metabolism as key drivers of osteosarcoma progression.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Bone niche-driven antitumor immune failure in osteosarcoma: Mechanisms and therapeutic implications (Review).Oncology letters · 2026Review
- Molecular characterization of cell dynamics during osteosarcoma progression.Translational oncology · 2026Article
- Single-cell mitophagy patterns dictate intercellular crosstalk in the tumor microenvironment to promote osteosarcoma progression.Translational cancer research · 2026Article
- Immune exclusion as a recurrent immune-escape state driving treatment resistance in osteosarcoma: insights from single-cell, spatial, and multi-omics studies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteosarcoma is a highly aggressive bone malignancy characterized by frequent metastasis and therapy resistance. Although mitophagy and pyruvate metabolism are increasingly recognized as critical metabolic regulators, their interaction in osteosarcoma remains poorly understood. The autophagy-related protein GABARAP, central to mitochondrial quality control, has not been systematically evaluated in osteosarcoma. Methods: Single-cell RNA sequencing (scRNA-seq) datasets (GSE162454, GSE237070) were analyzed to delineate cellular heterogeneity and malignant states, with prognostic clusters identified by Scissor and inferCNV. Tumor microenvironment (TME) composition and intercellular signaling were profiled using CellChat. Pathway enrichment and multi-omics integration across TARGET, GSE21257, and GSE32981 highlighted mitophagy-pyruvate coupling, which were further validated by spatial transcriptomics and Results: We mapped the osteosarcoma ecosystem and identified two malignant subpopulations, Ost_1 and Cho_2 (Mal_Ost/Cho), exhibiting high genomic instability, stemness, and poor prognosis. The osteosarcoma TME displayed profound immune remodeling, characterized by infiltration of T/NK cells alongside enrichment of immunosuppressive Tregs and M2-polarized macrophages. Enhanced MIF-mediated signaling between Mal_Ost/Cho and T/NK compartments suggested a key mechanism of immune evasion. Both malignant subtypes demonstrated coordinated activation of mitophagy and pyruvate metabolism, sustaining metabolic adaptation and tumor progression. Multi-omics integration pinpointed GABARAP as a central hub regulating this mitophagy-metabolism axis, spatially enriched within metabolic hotspots and immunosuppressive niches. Functionally, GABARAP depletion disrupted mitophagy flux, mitochondrial integrity, and energy production, thereby impairing osteosarcoma cell proliferation and migration. Conclusion: These findings reveal that GABARAP links mitophagy-driven metabolic adaptation with immune evasion, representing a key regulator and potential therapeutic target in osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.